Alder Biopharmaceuticals is a technology company.
Alder Biopharmaceuticals has raised $78.0M across 2 funding rounds.
Alder Biopharmaceuticals has raised $78.0M in total across 2 funding rounds.
Alder Biopharmaceuticals has raised $78.0M in total across 2 funding rounds.
Alder Biopharmaceuticals's investors include Avalon Ventures, Domain Associates, OrbiMed, Osage University Partners, Pivotal bioVenture Partners, RiverVest.
Alder Biopharmaceuticals is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of genetically engineered therapeutic antibodies. Its products primarily target autoimmune, inflammatory diseases, and migraine prevention. Alder’s lead candidates include eptinezumab, a monoclonal antibody for migraine prevention, and clazakizumab, targeting interleukin-6 for inflammatory conditions. The company serves patients suffering from chronic pain, migraines, autoimmune, and inflammatory diseases by developing novel antibody therapeutics that aim to transform current treatment paradigms. Alder has demonstrated growth momentum through advancing multiple drug candidates into clinical stages and forming strategic partnerships, such as with Bristol-Myers Squibb for rheumatoid arthritis treatment[1][2][3].
Founded in 2004 in Bothell, Washington, Alder Biopharmaceuticals was established to develop innovative therapeutic antibodies addressing unmet medical needs in chronic pain and inflammatory diseases. The founding team brought extensive industry experience in antibody therapeutics, which shaped the company’s focus on genetically engineered antibodies. Early traction came from advancing ALD518 (clazakizumab) and eptinezumab into clinical development, with pivotal moments including licensing agreements and clinical trial progress that validated their therapeutic approach[1][2][3].
Alder Biopharmaceuticals rides the growing trend of biologics and antibody therapeutics as precision medicines for complex diseases. The timing is favorable due to increasing prevalence of autoimmune and inflammatory conditions and a rising demand for targeted, effective treatments with fewer side effects. Market forces such as advances in genetic engineering, improved antibody design, and regulatory support for biologics work in Alder’s favor. By advancing novel antibody candidates, Alder contributes to expanding therapeutic options and influences the broader biotech ecosystem focused on innovative biologics[1][2].
Looking ahead, Alder Biopharmaceuticals is poised to continue advancing its pipeline, particularly in migraine prevention and inflammatory diseases, potentially expanding indications and commercial partnerships. Trends shaping its journey include growing acceptance of antibody therapeutics, advances in biologic manufacturing, and increasing patient demand for targeted therapies. Alder’s influence may evolve as it moves from clinical-stage development to commercialization, potentially becoming a key player in biologics for autoimmune and neurological conditions. Its strategic collaborations and diversified pipeline provide a strong foundation for future growth and impact in the biopharmaceutical industry[1][2][3].
Alder Biopharmaceuticals has raised $78.0M across 2 funding rounds. Most recently, it raised $38.0M Series D in April 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2012 | $38.0M Series D | Avalon Ventures, Domain Associates, OrbiMed, Osage University Partners, Pivotal bioVenture Partners, RiverVest | |
| Nov 1, 2007 | $40.0M Series C | Avalon Ventures, Domain Associates, OrbiMed, Osage University Partners, Pivotal bioVenture Partners, RiverVest |